Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 6/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 1.00 |
| ▸ | MGAM | O43451 | 5/20 | 0.93 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.93 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19745374 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL19557590 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL15593220 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL13317732 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL10028909 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL14268489 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL4319863 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL2435520 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL466573 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL13848041 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021067324-A1 | METHODS OF TREATING POMPE DISEASE | ACADEMIA SINICA (TW) | 2021-04-08 | — | — | WO | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | GLA 13/4885AGL 71/4885GAA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.